Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Comrad Releases New Medical Compression Socks in Stylish Tie Dye Colors


Compression socks manufacturer Comrad Socks is now making their best-selling product in tie-dye. Comrad believes that improving your health never has to go out of style. With five new, eye-catching designs, compression sock lovers are sure to find a unique style that is both comfortable and chic.

Comrad is on a mission to be the first brand of this kind, they make products that not only look and feel good, but also improve their customer’s wellbeing. Comrad believes that style shouldn’t have to be sacrificed in the name of health. That’s why their compression socks come in a variety of colors and patterns. Most recently, Comrad has introduced the tie-dye compression socks to their catalog of patterns.

Now available in five different tie-dye patterns, Comrad socks are going to ease moderate aches, pains, and discomfort, all while ensuring that customers look good. Comrad socks have been engineered to provide health benefits of graduated compression (increased circulation, more energy, prevention of DVT, edema, fatigue, swelling, varicose veins) yet were comfortable to wear every day for people of all ages.

Comrad socks are made from moisture-wicking nylon, magically thin, and breathable fibers that contour to the customer’s leg, SmartSilver Ions™, this proprietary product is silver antimicrobial eliminates odor which keeps feet fresh, and the knee-high socks are made to provide enhanced comfort with super soft toe and heel terry cushioning.

Reviewers agree. “Surprised at how well these socks made my feet and legs feel after 13 on my feet (hospital setting). I could instantly feel a cool sensation up and down from below my knees to toes – so cool! Usually by hour 8 I am dying to go home and put legs up…could have stood for four more hours easily.

I have worn them six times, and I still give the same review! Now I need to order another pair to have a laundry rotation. SO IMPRESSED!”

About Comrad Socks:

Comrad believes in taking smarter steps everyday. True wellness isn’t a tonic— it happens one step at a time, from the ground up. Through science, coupled with conscious design, Comrad strives to empower better living— for everything you care about to give you the momentum to keep flowing and squeezing more of what you want from each day.    

Share article on social media or email:

Rx and Illicit Drug Summit Awards Tim Robinson the 2022 Congressman Hal Rogers Beacon of Hope Award


Addiction Recovery Care President and CEO Tim Robinson (left) received the 2022 Hal Rogers Beacon of Hope Award. Presenting the award are U.S. Rep Hal Rogers and Nancy Hale, CEO of Operation UNITE.

“Since founding ARC and opening the doors to our first treatment center 12 years ago, I have made it my personal mission to serve and support those in our communities who have been impacted by addiction.”Tim Robinson

The Rx and Illicit Drug Summit named Addiction Recovery Care (ARC) President and CEO Tim Robinson the recipient of the 2022 Congressman Hal Rogers Beacon of Hope Award.

Robinson was recognized for his ongoing efforts to serve individuals and families impacted by the opioid and addiction crisis through ARC, which operates more than 30 programs in 21 Kentucky counties. ARC’s nationally recognized Crisis to Career model combines treatment with job training to prepare clients for life and success after ARC. The award is named for U.S. Rep. Hal Rogers (R-Ky.), who founded Operation UNITE in 2003, and is awarded annually at the Rx Summit to a changemaker working to address the addiction crisis and inspiring others to do the same.

“It is a tremendous honor and privilege to receive the 2022 Congressman Hal Rogers Beacon of Hope Award,” said Robinson. “Since founding ARC and opening the doors to our first treatment center 12 years ago, I have made it my personal mission to serve and support those in our communities who have been impacted by addiction. I am thankful to Congressman Hal Rogers, Operation UNITE, the Rx Summit and the countless other leaders who have inspired our movement and helped to pave the way.”

“It is an honor to present Tim Robinson with the Beacon of Hope Award,” Rogers said. “He turned his personal recovery journey into a network of hope for others battling addiction, bringing the mission of this summit full circle. So far, he has helped more than 41,000 individuals battling substance use disorder through Addiction Recovery Care, employing some of those graduates at ARC to continue helping others, and driving more than 900,000 miles to transport folks to a treatment facility last year when they had no other way. He is truly providing a beacon of hope when it is needed the most.”

Founded in 2012, the Rx Summit is an annual gathering of professionals from “federal to family,” including public health officials, business executives, academia, treatment providers, advocates, law enforcement, family members, and local, state, and federal agencies working to find solutions that address the drug misuse epidemic. The 2022 event is the first time since 2019 that stakeholders met in person, after two years of virtual events due to the COVID-19 pandemic.

“Our mission remains the same, to turn this epidemic around, to save lives, and to build hope for so many pursuing recovery,” said Nancy Hale, CEO of Operation UNITE, the educational advisor for Rx Summit. “That is what we are doing here this week, reconnecting with each other, learning from each other, and being reminded that there is hope.”

With more than 3,000 in attendance, the Rx Summit is the largest national collaboration of its kind and facilitates important connections to address this public health emergency. The Rx Summit focuses on prevention, treatment, and recovery, offering more than 90 sessions on nine educational tracks (advocacy, clinical, illicit drugs, prevention-overdose, prevention-primary, public safety, technology, trending topics, and treatment and recovery).

National Focus

Deaths due to drug overdose have topped 1 million for the first time since the Centers for Disease Control and Prevention began collecting data on the problem more than two decades ago. More than 101,000 drug overdose deaths occurred in the United States in the 12 months ending in June 2021, the largest number of drug overdoses for a 12-month period ever recorded.

President Joe Biden — whose FY2023 budget requests include $4.25 billion for drug policy efforts to fund research, prevention, harm reduction, treatment, recovery support services, and interdiction efforts to reduce the availability of illicit drugs in the U.S. — will share pre-recorded remarks during the 9 a.m. plenary session today. It is the fourth time a sitting U.S. president will address the Rx Summit during his term. Former presidential speakers have included President Biden in 2021, Donald J. Trump in 2019, and Barack Obama in 2016. Former President Bill Clinton addressed attendees in 2018.

“As we gather this week, we all know our communities are suffering,” said Doug Edwards, vice president, HMP Global, who directs the company’s Psychiatry & Behavioral Health Learning Network. “At the Rx Summit we come together to share what’s working, the importance of collaboration, and the spirit of recovery.”

At 4 p.m., there will be a media round table discussion with Dr. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA) in the Rx Summit Press Room, followed by the evening plenary session at 6 p.m. with Volkow, Dr. Lawrence Tabak, Acting Director of the National Institutes of Health, and Dr. Rebecca G. Baker, Director of the NIH Helping to End Addiction Long-term Initiative.

For the full agenda, registration, and more information, visit rx-summit.com.

ABOUT HMP GLOBAL

HMP Global is the force behind Healthcare Made Practical—and is an omnichannel leader in healthcare content, events, and education, with a mission to improve patient care. The company produces accredited medical education events – in person and online via its proprietary VRTX virtual platform – and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include the HMP Global Learning Network, healthcare’s most comprehensive source for news and information; Psych Congress, the largest independent mental health meeting in the U.S.; the Evolution of Psychotherapy, the world’s largest independent educational event for mental health professionals; the Leipzig Interventional Course (LINC), the leading, global gathering for interdisciplinary cardiovascular specialists; EMS World Expo, North America’s largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit hmpglobal.com.

MCG Health’s Dr. William Rifkin to Speak at ACMA National Conference


MCG Health's Dr. William Rifkin

MCG Health’s William Rifkin, MD, FACP, will speak at the ACMA National Conference on new clinical evidence for evaluating chest pain patients.

“I hope that [ACMA] attendees will be reminded of the importance of evidence-based guidelines and learn how new recommendations for chest pain patients should impact their clinical care,” said Dr. Rifkin.

MCG Health, part of the Hearst Health network and an industry leader in technology-enabled, evidence-based guidance, announces its Managing Editor, William Rifkin, MD, FACP, will present at the American Case Management Association (ACMA) National Conference happening May 1-4, 2022, in Dallas, Texas. The annual ACMA event brings together case management and transitions of care professionals to network, exchange ideas, engage with innovators in the field, and discover best practices that improve patient care outcomes. Conference session topics cover utilization management, value-based care, and social determinants of health.

Dr. Rifkin will present the session, “Evaluation of Chest Pain Patients: A New Paradigm,” on Monday, May 2, 2022, from 3:30 p.m. to 4:30 p.m. The release of an American College of Cardiology (ACC) clinical practice guideline concerning the evaluation and disposition of patients who present to the emergency department with chest pain has led to substantial discussion about how such patients should be assessed and treated. Dr. Rifkin’s session will review how these recent recommendations have the potential to decompress busy emergency departments and observation care units and significantly reduce unnecessary costs.

“I am honored to present at the ACMA conference alongside healthcare leaders from across the nation,” said Dr. Rifkin. “I hope that attendees will be reminded of the importance of evidence-based guidelines and learn how new recommendations for chest pain patients should impact their clinical care, specifically in terms of level of care determinations and need for further testing.”

Dr. Rifkin oversees research, guideline writing, and other content development focused on acute inpatient care. Before joining MCG, he was an Associate Professor of Clinical Medicine and the Director of the Internal Medicine Residency Program at Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, New York. Prior to that, he was an academic hospitalist and Associate Residency Program Director at two other New York hospitals and at the Yale Primary Care Internal Medicine Residency Program in New Haven, Connecticut. He has published research in the areas of hospital medicine and quality of clinical care. Dr. Rifkin graduated from the State University of New York Stony Brook School of Medicine, completed his internal medicine training at Lenox Hill Hospital in New York, and is board-certified in internal medicine.

For those interested in attending the ACMA National Conference, registration details and additional information can be found at: https://na.eventscloud.com/website/32436/.

About MCG Health

MCG, part of the Hearst Health network, provides unbiased clinical guidance that gives healthcare organizations confidence in delivering patient-centered care. MCG’s artificial intelligence and technology, infused with objective clinical expertise, enables its clients to prioritize and simplify their work. MCG’s world-class customer service ensures that clients maximize the benefits of licensing MCG solutions – demonstrating improved clinical and financial outcomes. For more information visit http://www.mcg.com or follow our Twitter handle at @MCG_Health.

About Hearst Health

The mission of Hearst Health is to help guide the most important care moments by delivering vital information into the hands of everyone who touches a person’s health journey. Care guidance from Hearst Health reaches the majority of people in the U.S. The Hearst Health network includes FDB (First Databank), Zynx Health, MCG, Homecare Homebase and MHK (formerly MedHOK). Hearst also holds a minority interest in the precision medicine and oncology analytics company M2Gen. Follow Hearst Health on Twitter @HearstHealth and LinkedIn @Hearst-Health.

Share article on social media or email:

Novel Treatment Effective for Sidewall Brain Aneurysm


The results show that the WEB device is safe and effective to use for sidewall aneurysms. Our ultimate goal is to provide our patients with the best possible treatment for their brain aneurysms.

A novel mesh plug that has been traditionally used to treat brain aneurysms occurring where the blood vessels branch out was found to be equally effective in treating aneurysms on the side of the vessel, according to a study published April 19 in the journal Radiology.

Aneurysms result from a weakness in the blood vessel wall that typically occurs where the vessel branches or bifurcates—where the vessel divides or forks into two branches. Untreated, an aneurysm can grow and rupture. A common treatment involving the placement of tiny platinum coils into the aneurysm has limitations.

“If the aneurysm has a wide neck, the coil might fall into the blood vessel and lead to clot formation and incomplete aneurysm occlusion,” said study lead author Nimer Adeeb, M.D., from the Department of Neurosurgery and Interventional Neuroradiology at Louisiana State University in Shreveport, Louisiana. “Many times, you end up putting a stent in the blood vessel to prevent the coils from falling out and to keep them compacted within the aneurysm. This can have its own complications and requires using blood thinners.”

A braided wire device known as the Woven EndoBridge (WEB) was developed to overcome those limitations. The device is placed inside the aneurysm under angiographic guidance, where it causes a clot to form, closing off the aneurysm and reducing the risk of bleeding without requiring supporting stents or blood thinners.

“After you put the WEB device through the neck of the aneurysm, it opens up,” Dr. Adeeb said. “Given that it’s bigger than the neck of the aneurysm, it usually stays in place. One quick procedure is usually enough for successful treatment.”

The U.S. Food and Drug Administration (FDA) approved the WEB device for wide-neck intracranial bifurcation aneurysms. Some specialists have used it off-label for the treatment of sidewall aneurysms, a type of wide-necked aneurysm that occurs at the side of a blood vessel rather than its bifurcation tip.

Research on the WEB device’s use in wide-necked sidewall aneurysms has been limited to studies with a small number of cases.

For the new study, Dr. Adeeb and colleagues compared the WEB device in bifurcation and sidewall aneurysms using a large database spanning more than 10 years from the WorldWideWEB consortium, a group of 23 academic institutions in North America, South America, Australia and Europe. Dr. Adeeb co-led the effort with Adam A. Dmytriw, M.D., from Massachusetts General Hospital in Boston.

A total of 683 intracranial aneurysms were treated using the WEB device in 671 patients. Of those, 572 were bifurcation aneurysms, and 111 were sidewall aneurysms. Propensity score matching, a way to increase the power of a study by accounting for differences in patients, resulted in 91 bifurcation and sidewall aneurysms pairs.

The complication rate was very similar between the two approaches.

“We found out that there is no significant difference using the WEB device in sidewall aneurysms compared with bifurcation aneurysms,” Dr. Adeeb said. “The results show that the WEB device is safe and effective to use for sidewall aneurysms.”

Dr. Adeeb hopes that the study will help drive a discussion about expanding the indications for the WEB device to include certain sidewall aneurysms.

As additional institutions continue to join the consortium, Dr. Adeeb and his colleagues are continuing the research, comparing the WEB device with other treatments for different types and locations of aneurysms. They also plan to track changes that happen to device shape and compaction over time and its relationship to aneurysm occlusion status.

“Our ultimate goal is to provide our patients with the best possible treatment for their brain aneurysms,” he said.

“Multicenter Study for the Treatment of Sidewall versus Bifurcation Intracranial Aneurysms with Use of Woven EndoBridge (WEB).” Collaborating with Drs. Adeeb and Dmytriw were Mahmoud Dibas, M.D., Jose Danilo Bengzon Diestro, M.D., Hugo H. Cuellar-Saenz, M.D., Ahmad Sweid, M.D., Sandeep Kandregula, M.D., Sovann V. Lay, M.D., Adrien Guenego, M.D., Leonardo Renieri, M.D., Sri Hari Sundararajan, M.D., Guillaume Saliou, M.D., Ph.D., Assala Aslan, M.D., Markus Möhlenbruch, M.D., Justin E. Vranic, M.D., Robert W. Regenhardt, M.D., Ph.D., Amey Savardekar, M.D., Ahmed Mamilly, M.D., Ivan Lylyk, M.D., Paul M. Foreman, M.D., Jay A. Vachhani, M.D., Vedran Župančić, M.D., Muhammad U. Hafeez, M.D., Caleb Rutledge, M.D., Muhammad Waqas, M.B.B.S., Carmen Parra Farinas, M.D., Vincent M. Tutino, Ph.D., Yasuaki Inoue, M.D., Shervin Mirshahi, M.D., James D. Rabinov, M.D., Yifan Ren, M.D., Clemens M. Schirmer, M.D., Ph.D., Mariangela Piano, M.D., Anna L. Kühn, M.D., Ph.D., Caterina Michelozzi,,M.D., Stéphanie Elens, M.D., Robert M. Starke, M.D., Ameer Hassan, D.O., Arsalaan Salehani, M.D., Peter Sporns, M.D., Alex Brehm, M.D., Jesse Jones, M.D., Marios Psychogios, M.D., Julian Spears, M.D., M.S., Boris Lubicz, M.D., Ph.D., Pietro Panni, M.D., Ajit S. Puri, M.D., Guglielmo Pero, M.D., Christoph J. Griessenauer, M.D., Hamed Asadi, M.D., Ph.D., Christopher J. Stapleton, M.D., Adnan Siddiqui, M.D., Andrew F. Ducruet, M.D., Felipe C. Albuquerque, M.D., Peter Kan, M.D., Vladimir Kalousek, M.D., Pedro Lylyk, M.D., Srikanth Boddu, M.D., M.Sc., Jared Knopman, M.D., Mohammad A. Aziz-Sultan, M.D., Nicola Limbucci, M.D., Pascal Jabbour, M.D., Christophe Cognard, M.D., and Aman B. Patel, M.D. For the WorldWideWEB Consortium.

Radiology is edited by David A. Bluemke, M.D., Ph.D., University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, and owned and published by the Radiological Society of North America, Inc. (https://pubs.rsna.org/journal/radiology)

RSNA is an association of radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation. The Society is based in Oak Brook, Illinois. (RSNA.org)

For patient-friendly information on brain imaging, visit RadiologyInfo.org.

First-to-market Independent Light Treatment Service Expands Footprint


Phototherapy Treatment

Kristen Miller, CEO of Array Skin Therapy has announced plans to franchise the concept, ten years after co-founding the company in 2011. Array Skin Therapy helps people overcome frustrating symptoms of skin conditions with narrowband UVB and excimer laser light treatment, resulting in improved self-confidence and regained control over one’s lifestyle. Narrowband UVB (NBUVB) is defined as light in the 308-312 nm range, identified as the optimal wavelength for treating autoimmune and inflammatory skin conditions. Kristen currently operates five Array Skin Therapy locations in Southern California with plans to expand access to light treatment across the nation.

In 2010, Kristen noticed patients faced many barriers to receiving light therapy while working as a nurse practitioner at a large medical center light treatment facility. Barriers to care included difficulty scheduling appointments, long wait times and expensive parking. Some patients in need of treatment were placed on a waitlist and never received a call.

Kristen recognized that an alternative model was needed in order to increase patient access to light treatment, thereby improving patient adherence and outcomes. In 2011 Kristen launched Array Skin Therapy, an independent light treatment service built with patient convenience in mind.

Array provides light treatment only. The specialized nature of the company allows for an efficient and highly supportive patient experience. Array clinics are conveniently located within the community and offer free parking. Appointments are flexible and easy to schedule due to Array’s team of dedicated front desk associates. Treatment is safe and effective, delivered by nurses, and overseen by nurse practitioners and collaborating physicians.

According to market research, the global light treatment industry was valued at US$765.9 million in the year 2020, and is projected to reach a revised size of US$943.5 million by 2026.

With franchise expansion, Array Skin Therapy will offer franchisees the opportunity to invest in an expanding field, while making a difference in the lives of those living with skin conditions.

Ideal candidates for franchise ownership are experienced, licensed nurse practitioners with entrepreneurial tendencies. Partnerships with non-healthcare providers may be permitted in compliance with state and federal regulations.

###

Media Contact

Name: Bevens Goodman, Chief Branding Officer

Email: bevens@arrayfranchise.com

Organization: The Array Group

Address: 2990 S. Sepulveda, Suite 208, Los Angeles, CA 90064

Phone: 213-855-2224

Website: http://www.arrayfranchise.com

Share article on social media or email:

Scientist.com and New Motion Beverages Join Forces to Celebrate San Diego’s Biotech and Craft Brewing Industries


“Brewing collaborations are a great way for two companies working in different industries to highlight their commitment to using innovative approaches to improve human health.”—Kyle Pool, CEO & Founder of New Motion Beverages and Embolden Beer Company.

Scientist.com, the biopharma industry’s leading R&D marketplace, announced today that it partnered with New Motion Beverages to create a hard sparkling tea called “Tropical Brainstorm.” The companies teamed up to celebrate a thriving San Diego cultural scene that includes many world-famous biotech and pharmaceutical companies and craft beverage breweries.

“We were thrilled to collaborate with New Motion, which shares our commitment to innovation, ethical sourcing and good health,” stated Kevin Lustig, PhD, CEO and Founder of Scientist.com. “Like Scientist.com in the biotech space, New Motion is committed to working with the most highly qualified and sustainable suppliers for its community-grown hops, farm-fresh fruit and ethically sourced teas.”

Located in the heart of San Diego’s craft brewing district, New Motion Beverages and Embolden Beer Company opened in 2020 under the mantra of inclusivity and diversity. Today, New Motion offers more than half a dozen fruit-forward hard sparkling teas on tap and in cans, while Embolden offers IPAs, lagers and sours, all brewed onsite at their Miramar location.

“Brewing collaborations are a great way for two companies working in different industries to highlight their commitment to using innovative approaches to improve human health,” stated Kyle Pool, CEO & Founder of New Motion Beverages and Embolden Beer Company. “Scientist.com and New Motion both focus on constant experimentation, high quality standards and a passion for healthy living!”

Founded in Solana Beach in 2007, Scientist.com has grown into one of the country’s fastest-growing privately owned companies, appearing on Inc. magazine’s annual list of the 500 fastest-growing US private companies for five consecutive years (2017-2021). This is the second time Scientist.com has collaborated with a local craft brewery to highlight San Diego’s world-famous biotech and craft brewery industries; in 2021 it teamed up with Solana Beach’s Pizza Port to create “The Local Experiment,” a hazy IPA.

New Motion Beverages will be hosting a “Tropical Brainstorm” release party on Thursday, April 28, 2022, at its Miramar location from 5-8 pm PT. For more details or to RSVP, visit https://www.eventbrite.com/e/tropical-brainstorm-release-party-tickets-310787482727?aff=SocialMedia

About Scientist.com

Scientist.com is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saves time and money, reduces risk and provides access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 80 biotechnology companies and the US National Institutes of Health (NIH).

Visit scientist.com to learn more.

Join Scientist.com on social media: LinkedIn, Twitter, YouTube, Facebook and Instagram

Share article on social media or email:



Configo Health Partners with Riley Children’s Health to Reimagine the Use of Benchmark Data and Analytics in Pediatric Care


Our partnership with Configo allows us to benefit from leading edge tools and services built specifically for children’s health systems. – Gil Peri, President of Riley Children’s Health

Configo Health, a leading provider of analytical benchmarking solutions for pediatric hospitals, today announced a groundbreaking 5-year co-development partnership with Riley Children’s Health. This co-development partnership will design a best-in-class pediatrics analytics platform utilizing Configo’s new pediatric benchmarking tools.

As Indiana’s only comprehensive children’s health system, Riley Children’s is committed to improving child health in the state and beyond. They will license Configo’s Opus pediatric benchmarking platform, including its flagship Quality & Safety module, and will serve as the launch customer for its new Opus Health Equity module. Opus Health Equity enables hospital leadership to proactively review performance and peer-benchmarks to ensure equity in quality, safety and outcomes.

“Riley Children’s Health is committed to utilizing data and analytics to improve child physical and behavioral health. We have recruited top talent who commit themselves to caring for children. Through this co-development partnership, we will be able to utilize data to support our team in their decision making and focus on delivering the best outcomes”, said Gil Peri, President of Riley Children’s Health. “Our partnership with Configo allows us to benefit from leading edge tools and services built specifically for children’s health systems. We will be co-developing analytic solutions that will amplify our team’s ability to proactively care for the patients and families we serve.”

Configo will also embed members of its analytics team, led by Warren Boudreau, Vice President of Client Success at Configo, within Riley Children’s as part of a co-sourcing approach to the delivery of internal analytical services. The development of the Riley Children’s Pediatric Analytic Resource Center (PARC) will enable the organization to identify proactive ways to support patients and families.

“We are thrilled to be deepening our relationship with Riley Children’s Health and to have the opportunity to transform the role that data plays in improving patient outcomes, staff experience and operating efficiency,” said Craig Manson, CEO of Configo Health, “Our clients continually share with us the challenges of recruiting and retaining analytical talent. We believe co-sourcing solves that problem without replacing internal hospital capability.”

Dr. Elaine Cox, Chief Medical Officer at Riley Children’s added, “We are committed to reducing inequity in patient outcomes but have lacked access to credible data to allow us to focus both our improvement efforts and assess our success. Configo’s Health Equity benchmarking tools will change that dynamic allowing us to really understand how we compare to our peers and have the opportunity to share best practices.”

About Configo Health, Inc.

Configo Health Inc. is a healthcare data and analytics company, focused exclusively on pediatrics, that helps children’s hospitals and their teams make better decisions through the use of timely, trusted and actionable insight. Through its OPUS benchmarking platform, Configo currently serves the needs of Quality & Safety and Diversity, Equity & Inclusion leadership with its Surgery proposition launching later this year. Configo Health has offices in Washington D.C., New York City and Asheville, NC.

About Riley Children’s Health – Indianapolis, IN

Riley Children’s Health at Indiana University Health is a leading children’s health system and Indiana’s only comprehensive statewide pediatric health system. Riley Children’s Health offers comprehensive pediatric care ranging from routine primary care to the most complex care. The health system connects 200 primary care and 400 specialty care physicians in 19 communities throughout the state of Indiana. Riley Children’s Health has the state’s only pediatric research center dedicated to discovery.

Share article on social media or email:

Workplace First Aid Kits Require Updates to Meet Industry Standard


News Image

“Each work environment is unique, and therefore making additions to the minimum requirements of any First Aid Kit should take place based on the hazards and injury that could occur at that specific worksite.” – Todd VanHouten

The International Safety Equipment Association (ISEA) has received American National Standards Institute (ANSI) approval for ANSI/ISEA Z308.1-2021 American National Standard for Minimum Requirements for Workplace First Aid Kits and Supplies. This revision, the fifth since the standard was first published in 1978, builds upon the initial objective to ensure that items needed to treat the most common types of injuries and sudden illnesses encountered in the workplace are readily accessible and available.

The effective date of this standard is October 15, 2022. Thereafter, first aid kits in compliance with this standard shall contain the required supplies, and the supplies shall meet the applicable performance requirements.

“Employers should begin to check their first aid cabinets against the new standard, and make the recommended changes,” said Todd VanHouten, Director of Product Development & Innovation at Cintas First Aid & Safety, and Chair of the ISEA First Aid Product Group. “While compliance with the standard is recommended, updating first aid stations, kits and protocols goes beyond compliance. The discussions and recommendations in this standard can help guide an organization’s overall first aid program, ultimately helping to provide proper and timely treatment for all employees.”

This edition retains the kit classification (Class A or Class B, based on workplace environment) established in 2015 and includes several notable updates:

  • A Foil Blanket is Now Mandatory: This was considered based on an assessment of similar international standards and in recognition of the multiple purposes that the item can serve, such as treating hypothermia, acting as a windbreaker, or worn as an emergency waterproof wrap.
  • More Specificity for Tourniquets: The standard helps to distinguish tourniquets from those types of bands used to draw blood, which are not as effective in preventing blood loss, as is intended.
  • Greater Guidance on Bleeding Control Kits: The standard provides additional details on designated bleeding control kits, which contain more advanced first aid supplies to immediately treat life-threatening external bleeding.
  • Enhanced Workplace Hazard Assessment: Included in the updated standard is a more robust discussion to assist the employer in assessing risks, identifying potential hazards, and selecting additional first aid supplies relevant to a particular application or work environment.

“Each work environment is unique, and therefore making additions to the minimum requirements of any First Aid Kit should take place based on the hazards and injury that could occur at that specific worksite,” said VanHouten. “Employers should conduct a thorough workplace hazard assessment to help them determine which supplies to augment.”

Join ISEA and its First Aid Product Group for a free webinar on May 12 at 2pm ET to learn about the updated standard, vital updates, and how to ensure workplace first aid kits remain Z308.1 compliant. The webinar will be presented by recognized leaders in the research and development of first aid treatment items and training, including representatives from Acme United, Certified Safety, Cintas Corporation, and Medique Products. Register here: https://bit.ly/3M6lgQc

ANSI/ISEA Z308.1-2021 was developed by ISEA’s First Aid Product Group and approved by key stakeholders representing construction groups, technology corporations, testing laboratories, utility companies, and others.

The standard can be purchased for $65 from ISEA’s First Aid Standard page or through any licensed resellers.

Share article on social media or email:

Georgia Dermatology Center merges with Olansky Dermatology & Aesthetics


News Image

“Having Georgia Dermatology Center merge with us is an honor, and we’re confident this collaboration will have an extremely positive impact on patients,” says Dr. Jodi Ganz, Managing Partner for Olansky Dermatology & Aesthetics.

Beginning this month, Olansky Dermatology & Aesthetics – Atlanta’s premier full-service dermatology practice – will be joining forces with Georgia Dermatology Center in Cumming. The union of two acclaimed, trusted dermatology practices gives patients added confidence and convenience when choosing the right source for their skin-related medical needs.

“Olansky and Georgia Dermatology Center have a long history of working together to achieve the best patient outcomes,” says Dr. Jodi Ganz, Managing Partner for Olansky Dermatology & Aesthetics. “Having Georgia Dermatology Center merge with us is an honor, and we’re confident this collaboration will have an extremely positive impact on patients.”

Located in the same complex as Northside Hospital Forsyth, Georgia Dermatology Center’s trusted and acclaimed providers, staff, and top-tier level of service will remain the same. Dr. Alexander Gross, a true thought leader in the field, will continue to lead the charge, powered by his award-winning background. Dr. Gross’ leadership includes serving as a fellow of the American Academy of Dermatology and as past president of the Georgia Society of Dermatology. His compassion for patients can be seen by his tireless volunteerism for charitable organizations such as the American Cancer Society and Gateway Center. The latter is an Atlanta homeless shelter that has its own medical clinic.

Dr. Gross adds to Olansky expertise in both general dermatology and cosmetic procedures. He will be offering the addition of services such as thread lifts and tumescent liposuction of the leg, thigh, midsection, neck, and face. Georgia Dermatology Center’s already impressive suite of services will be bolstered by several additions from the Olansky team. These include more aesthetics offerings and Mohs surgery, an advanced surgical procedure that removes skin cancer effectively using only local anesthesia.

Additionally, the merger will allow patients to take advantage of a larger group of accepted insurance options. This widens the scope of patient access without incurring out-of-network fees.

The full transition of the merger will span across 2022 as more enhancements and patient opportunities unfold.

“We’re excited to grow in this manner, and we’re working closely with Dr. Gross, formulating plans for the future,” says Dr. Ganz. “However, at the end of the day, it’s the patients who benefit the most, and that’s our overall goal.”

Appointments can be made by calling 404-355-5484.

Georgia Dermatology Center, 1505 Northside Blvd., Suite 1500, Cumming, Georgia.

Olansky Dermatology & Aesthetics is your dermatology solution. Our ability to provide full-service dermatology to patients of all ages is a distinct benefit to choosing our 40-year-old practice. We offer medical, surgical, cosmetic, and aesthetic services to our patients, and even same-day appointments when possible. This makes us not only a convenient solution for your family, but a comprehensive one as well. With services including our in-house Mohs surgery for skin cancer, advanced laser therapy for psoriasis or our aesthetic services for skin rejuvenation, Olansky Dermatology & Aesthetics can handle all of your skin concerns. For more details, visit our website at OlanskyDermatology.com or call 404-355-5484.

Interviews are available upon request.

Share article on social media or email:

Bristol Extracts Launches CBD Product Line, Bristol Extracts Hemp Wellness Co.


BE Product Shot

Bristol Extracts Hemp Wellness Co. products

We have invested in state-of-the-art technologies and established methods to nano-emulsify our CBD, CBN, and other cannabinoids.

Bristol Extracts is proud to announce the launch of their new CBD product line, Bristol Extracts Hemp Wellness Co. Looking to shake up the hemp and CBD industry with a bespoke approach to plant science, Bristol Extracts launched with four distinct lines, Replenish, Pain, Sleep, and Chill, that deliver hemp extracts of superb quality.

Now available exclusively at http://www.bristolextracts.com, this revolutionary new line of nano-emulsified CBD products sets them apart from most major competitors on the market. Unlike traditional CBD products, nano-sized CBD is so small that it has the ability to penetrate the “blood-brain barrier” of cells. This allows Bristol Extracts Hemp Wellness Co. CBD products to take effect in as little as 10-15 minutes, providing products packed with powerful antioxidants, natural essential oils, and high-quality cannabinoids. Nano-emulsified CBD also allows for 90% absorption of said cannabinoids, providing an effect 15 times more potent than other traditionally ingested products.

“We have invested in state-of-the-art technologies and established methods to nano-emulsify our CBD, CBN, and other cannabinoids,” said Eric Blazak, founder of Bristol Extracts and Bristol Extracts Hemp Wellness Co. “This helps us increase bioavailability and subsequent bioactivity within the body’s systems and anatomy.”

Not only has Bristol Extracts engineered the hemp phenotypes they grow, but they also oversee every step of CBD creation on-site — from extraction to processing to post-production. This ensures only the highest quality hemp and other natural ingredients are present in the products offered by Bristol Extracts Hemp Wellness Co.

Starting at an introductory price of $69.99 for balms and oils and $89.99 for tinctures, Bristol Extracts Hemp Wellness Co. products are sure to deliver impressive, long-lasting results in a matter of minutes.

About Bristol Extracts Hemp Wellness Co.

Bristol Extracts was established by Juan Guevara and Eric Blazak because they believe in the power of plant medicine. By investing in CBD, a true alternative to dangerous pharmaceuticals and opioids, Bristol Extracts and their exclusive product line, Bristol Extracts Hemp Wellness Co. is able to help provide users with relief from a multitude of daily ailments. Everything is created in-house, with seed-to-shelf quality control, ensuring that millions of consumers are provided with the best benefits of the cannabinoids they are purchasing.

Share article on social media or email: